Abstract Details

Regional Myelin-Specific MRI Abnormalities in Susac Syndrome Suggests Demyelination is a Pathologic Feature
Multiple Sclerosis
P6 - Poster Session 6 (11:30 AM-1:00 PM)
9-021

SuS is an autoimmune disease of the microvasculature in the brain, retina and inner ear. Lesions presumed to be microinfarcts classically involve the CC, but can also be observed in the IC. Although biopsies in Sus are rare, demyelination has been reported. We investigated whether myelin abnormalities could be detected in vivo in SuS using MWI, an advanced MRI technique that provides a quantitative measurement of myelin, termed the myelin water fraction (MWF). The mean MWF reflects the average myelin present within a region of interest (ROI) while the standard deviation (SD) is an indicator of myelin heterogeneity within that ROI.

To assess myelin water imaging (MWI) findings in patients with Susac Syndrome (SuS) and multiple sclerosis (MS) in the corpus callosum (CC) and internal capsules (IC).

MWI data were acquired from 7 Definite or Probable SuS patients following the European Susac Consortium diagnostic criteria, and 7 MS patients following the 2010 McDonald criteria using a gradient and spin echo sequence (GRASE) on a 3T scanner. The MWF of non-lesional tissue in the CC (genu, body, and splenium), and IC was compared between SuS and MS participants

In the CC, MWF was lower in SuS than MS (-20%, p=0.09), and significantly reduced in the body of the CC (-27%, p=0.02), with similar heterogeneity between SuS and MS (p=1.0). In the IC, MWF was significantly higher in SuS compared to MS (+47%, p<0.001) with greater heterogeneity in SuS (+46%, p<0.001).

SuS patients MWF measurements differed regionally from MS patients, who are known to have reduced myelin compared to healthy controls. These findings from seven SuS patients suggest that non-lesional myelin abnormalities may also be a pathologic feature of SuS.

Authors/Disclosures
Poljanka Johnson (University of British Columbia)
PRESENTER
Ms. Johnson has nothing to disclose.
Jillian Chan, MD No disclosure on file
Irene Vavasour, PhD (University of British Columbia) Dr. Vavasour has nothing to disclose.
No disclosure on file
Lisa Eunyoung Lee Lisa Eunyoung Lee has nothing to disclose.
Heather Yong, MD (Alberta Health Services) Dr. Yong has nothing to disclose.
Vanessa Wiggermann (University of British Columbia) No disclosure on file
Cornelia Laule, PhD (University of British Columbia) The institution of Dr. Laule has received research support from Multiple Sclerosis Society of Canada. The institution of Dr. Laule has received research support from Natural Sciences and Engineering Research Council of Canada (NSERC). The institution of Dr. Laule has received research support from International Collaboration on Repair Discoveries (ICORD).
Andrew Woolfenden, MD No disclosure on file
Anthony Traboulsee, MD (University of British Columbia) Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sanofi. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for EMD Serono. Dr. Traboulsee has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Traboulsee has received research support from Roche. The institution of Dr. Traboulsee has received research support from Genzyme. The institution of Dr. Traboulsee has received research support from Consortium of MS Centers. The institution of Dr. Traboulsee has received research support from MS Canada. Dr. Traboulsee has received personal compensation in the range of $500-$4,999 for serving as a Workshop Chair with Consortium of MS Centers.
David K. Li, MD (University of British Columbia) Dr. Li has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Biogen. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Academy of Health Care Learning. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Sanofi-Genzyme. Dr. Li has received personal compensation in the range of $0-$499 for serving on a Speakers Bureau for Consortium of MS Centers.
Roger Tam, PhD (University of British Columbia, MS/MRI Research Group) The institution of Dr. Tam has received research support from Natural Sciences and Engineering Research Council. The institution of Dr. Tam has received research support from Praxis Spinal Cord Institute.
Shannon Kolind, PhD, MSc, BSc (University of British Columbia) Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Novartis. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Kolind has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Roche. The institution of Dr. Kolind has received research support from Sanofi Genzyme. The institution of Dr. Kolind has received research support from Roche. The institution of Dr. Kolind has received research support from Biogen.
Robert L. Carruthers, MD Dr. Carruthers has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Novartis. Dr. Carruthers has received personal compensation in the range of $0-$499 for serving as a Consultant for Roche and Genentech. The institution of Dr. Carruthers has received research support from Roche and Genentech .